Ffecting Cognitive Function News Today

A longitudinal dataset indicating the utility of plasma pTau for patient selection in clinical trials of patients with mild Alzheimer's Disease (AD) and the likely therapeutic benefit of oral Xanamem in this population SYDNEY, March 30, 2023 /PRNewswire/ -- Actinogen Medical ASX: ACW ("ACW" or "the Company")is pleased to announce that its Chief Medical Officer, Dr Dana Hilt will make an oral presentation to the International Conference on Alzheimer's and Parkinson&#39...

Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1]which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamemmay assist where treatment by anti-depressant medication alone is inadequate SYDNEY, Dec. 14, 2022 /PRNewswire/ --Actinogen Medical Limited (ASX: ACW)is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression clinical trial that will meas...